RNAi specialist Arrowhead reports loss of $58.7M in FY 2014

Arrowhead Research ($ARWR) reported a net loss of $58.7 million in fiscal year 2014, up from $31.7 million in FY 2013. R&D expenses nearly tripled in FY 2014 to $23.1 million, as the company races to develop a commercial therapy before investors lose patience. Its stock fell about 50 cents on the Nov. 25 news and now stands at a little under $6. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.